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Abstract
Background: There is evidence that some ovarian tumours evoke an immune response, which can be assessed by
tumour infiltrating lymphocytes (TILs). To facilitate adoption of TILs as a clinical biomarker, a standardised method
for their H&E visual evaluation has been validated in breast cancer.
Methods: We sought to investigate the prognostic significance of TILs in a study of 953 invasive epithelial ovarian
cancer tumour samples, both primary and metastatic, from 707 patients from the prospective population-based
SEARCH study. TILs were analysed using a standardised method based on H&E staining producing a percentage
score for stromal and intratumoral compartments. We used Cox regression to estimate hazard ratios of the
association between TILs and survival.
Results: The extent of stromal and intra-tumoral TILs were correlated in the primary tumours (n = 679, Spearman’s
rank correlation = 0.60, P < 0.001) with a similar correlation in secondary tumours (n = 224, Spearman’s rank
correlation = 0.62, P < 0.001). There was a weak correlation between stromal TIL levels in primary and secondary tumour
samples (Spearman’s rank correlation = 0.29, P < 0.001) and intra-tumoral TIL levels in primary and secondary tumour
samples (Spearman’s rank correlation = 0.19, P = 0.0094). The extent of stromal TILs differed between histotypes (Pearson
chi2 (12d.f.) 54.1, P < 0.0001) with higher levels of stromal infiltration in the high-grade serous and endometriod cases. A
significant association was observed for higher intratumoral TIL levels and a favourable prognosis (HR 0.74
95% CI 0.55–1.00 p = 0.047).
Conclusion: This study is the largest collection of epithelial ovarian tumour samples evaluated for TILs. We have shown
that stromal and intratumoral TIL levels are correlated and that their levels correlate with clinical variables such as tumour
histological subtype. We have also shown that increased levels of both intratumoral and stromal TILs are associated with
a better prognosis; however, this is only statistically significant for intratumoral TILs. This study suggests that a clinically
useful immune prognostic indicator in epithelial ovarian cancer could be developed using this technique.
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Background
Ovarian carcinoma is the fourth most common cancer
in women worldwide but it is responsible for the most
fatalities due to gynaecological malignancy in the devel-
oped world [1]. Known prognostic factors include tumour
characteristics (grade, histotype, clinical stage), patient
factors (age, fitness, smoking status), treatment factors,
and the response to first line treatment [2].
There is evidence that some epithelial ovarian tumours
evoke an immune response and that this affects prognosis
[3]. Several studies have investigated the effect of various
subtypes of immune cell response on prognosis in ovarian
cancer [4–20]. These studies have been of modest sample
sizes ranging from 9 through to 500 tumours. Immunohis-
tochemistry was used to investigate the immune response,
but they have shown conflicting results (outlined in
Table 1), though most suggest that CD3(+) and CD8(+)
tumour infiltrating lymphocytes are associated with a
favourable outcome. Immune infiltration has also been
shown to be enriched in some molecular subtypes of
ovarian cancer [21]. The anti-tumour immune response
is perhaps most easily assessed morphologically using
standard histopathology based on haematoxylin and
eosin (H&E) staining. Therefore this may represent the
most promising avenue for clinical translation. How-
ever, no study has yet investigated the effect of total
tumour infiltrating lymphocytes (TILs) on prognosis in
ovarian cancer.
There have been calls for the use of a standardised
method of evaluating TILs in cancer and incorporating
it clinically as a prognostic variable [22]. Haematoxylin
and eosin (H&E) staining and visual analysis is a recognised
cheap and clinically accessible method of evaluating TILs.
A standardised method for H&E visual evaluation of TILs
has been validated in the context of breast cancer [23].
We investigated the pathological and prognostic sig-
nificance of TILs in epithelial ovarian cancer. We used a
standardised method of TIL evaluation and a large
prospective population-based study of epithelial ovarian
cancer to achieve this.
Methods
Study population
The SEARCH ovarian cancer study is an ongoing,
population-based ovarian cancer case–control study,
covering the regions served by the East Anglia and
West Midlands cancer registries in the UK. All patients
diagnosed in East Anglia with invasive epithelial ovarian
cancer under the age of 70 years since 1991, and still alive
in 1998 when recruitment started are eligible to partici-
pate. Details of this study and its participants have been
published previously [24]. To date over 2500 women
with epithelial ovarian cancer have been recruited. We
have retrieved archival, formalin-fixed, paraffin-embedded
(FFPE) tumour tissue from the primary surgery from 707
SEARCH participants with invasive epithelial ovarian
cancer. A total of 953 samples have been retrieved in-
cluding tumour from both primary and metastatic sites.
Survival time data were available through the regional
cancer registry which obtains notification of deaths by
death certificate flagging through the Office of National
Statistics. The lag times for this are a few weeks for cancer
deaths and two months to a year for non-cancer deaths.
In addition, the cancer registry checks vital status by
querying the National Health Service Strategic Tracing
Service. Vital status was ascertained at the end of June
2015 and all analyses were censored on 31 December
2014 to allow for delay in reporting of vital status. Ovarian
cancer specific mortality was defined as deaths where
ovarian cancer was listed as the cause of death on Parts
1a, 1b, or 1c of the death certificate.
Evaluation of tumour infiltrating lymphocytes
Formalin-fixed, paraffin-embedded tumour samples were
sectioned and stained using hematoxylin and eosin. The
morphology was reviewed by a gynaecological patholo-
gist (MJ-L). Full face stained sections were then scanned
and the digital images were used for evaluation of TILs.
Evaluation of TILs was performed by manual visual
assessment of percentage area covered by lymphocytes,
following a standardised method as described in Salgado
et al. [23]. In this method the area within the tumour
border is selected, the intra-tumoral and stromal compart-
ment are defined, only areas of mononuclear lymphocytic
infiltrate are included, and the percentage area is assessed
at low (4× objective) and high magnification (10× object-
ive). The percentage categories used were 1%, 5% and the
nearest 10% up to 100%. The intra-tumoral and stromal
compartments were scored separately. The intra-tumoral
and stromal TILs were classified into three groups for the
purpose of analysis – very low (1%), low (5%) and high
(≥10%). Representative examples of tumours with very
low, low and high TIL are shown in Fig. 1.
Statistical analysis
The proportion of tumours in the three TIL score categor-
ies by other histopathologic characteristics was compared
using the Pearson χ2- test. Multi-variable Cox regression
was used to assess the association between TILs and
disease-specific mortality. Follow-up time was adjusted for
delayed study entry by using the date of study entry as the
start of time at risk (left truncation) [25]. All models were
adjusted for FIGO stage (stage 1–4 treated as an ordinal
variable), histotype (seven categories) and age at diagnosis.
Analyses were censored at 10-years of follow-up or on
death from a cause other than ovarian cancer. Stata 14
(Stata Corp, College Station, Texas, USA) statistical soft-
ware was used for all analyses.
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Results
Data were available for 953 invasive epithelial ovarian
tumours (primary and/or metastatic), from 707 women.
Of these, primary tumour material was available for 682
cases, omental tumour material for 161 cases and other
metastasis material was available for 114 cases (Fig. 2).
The clinical characteristics (age at diagnosis and stage)
of these cases by histotype are shown in Table 2.
There was a moderately strong correlation between
the extent of stromal and intra-tumoral TIL levels in the
primary tumour (n = 679, Spearman’s rank correlation = 0.60,
P < 0.001) with a similar correlation in secondary tumours
(n = 224, Spearman’s rank correlation = 0.62, P < 0.001).
Secondary tumour samples were either omental metastases
or metastases at other sites. We used the data for the omen-
tal metastases in preference to data for other metastases if
present; otherwise the data from the other metastases was
used. We also evaluated the correlation between TIL levels
in primary and metastatic tumours using data from the 196
women for whom both a primary and a secondary tumour
sample was available. There was a statistically significant but
weak correlation between stromal TIL levels in primary
and secondary tumour samples (Spearman’s rank cor-
relation = 0.29, P < 0.001) and intra-tumoral TIL levels
in primary and secondary tumour samples (Spearman’s
rank correlation = 0.19, P = 0.0094) (Table 3).
Fig. 1 Representative examples of tumours with very low, low and
high TIL
Fig. 2 Number of patients by available tumour sample
Table 2 Clinical characteristics of ovarian cancer cases included
in this study
Histotype Mean age
at diagnosis
Stage
I/II (%a) III/IV (%) Unknown Total
LGSC 54.0 5 (25) 15 (75) 3 23
HGSC 57.5 80 (29) 192 (71) 42 314
Mucinous 52.7 39 (91) 4 (9) 5 48
Endometrioid 54.5 113 (91) 11 (9) 11 135
Clear cell 55.7 70 (91) 7 (9) 5 82
Other 56.3 39 (64) 22 (36) 8 69
Borderline 49.6 33 (100) 0 (0) 3 36
Total 55.7 379 (60) 251 (40) 77 707
LGSC low-grade serous cancer, HGSC high-grade serous cancer
apercent of those with known stage
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The extent of stromal TIL levels differed between histo-
types (Table 4, Pearson chi2 (12d.f.) 54.1, P < 0.0001) with
higher levels of stromal infiltration in the high-grade serous
and endometriod cases. However, there was little difference
in the degree of intra-tumoral infiltrating lymphocytes by
histotype (Pearson chi2 (12d.f.) = 15.0, P = 0.24).
We assessed the impact of tumour infiltrating lympho-
cytes on ovarian cancer specific mortality after diagnosis
using multi-variable Cox proportional hazards regression.
The extent of tumour infiltrating lymphocytes in three
categories (<5%, 5–9%, ≥10%) was treated as an ordinal
variable in the model. An increase in stromal TIL levels
was associated with a slightly better prognosis but the dif-
ference was not statistically significant (HR 0.87 95% CI
0.74–1.02 p = 0.091). A slightly stronger and nominally
significant association was observed for intra-tumoral TIL
levels (hazard ratio = 0.74, P = 0.047). When the extent of
both stromal and intra-tumoral TIL levels were included
in a multi-variable model the effect of the intra-tumoral
TIL levels was similar (HR 0.76 95% CI 0.58–1.00
p = 0.047), but the association of the stromal lymphocytes
was attenuated (HR 0.97 95% CI 0.79–1.19 p = 0.78).
There was little evidence for heterogeneity of effect of
intra-tumoral TIL levels by histotype, although the effect
was strongest in the high-grade serous cases (HR 0.70
95% CI 0.50–0.97 p = 0.034).
Discussion
This study is the largest collection of epithelial ovarian
tumour samples evaluated for TILs, with almost double
the number of tumour samples as the largest published
study to date [12]. This is also the first time this standar-
dised H&E visual assessment method of TIL evaluation
has been used in ovarian tumours.
We have shown that TILs as assessed by stromal
lymphocyte levels correlate with clinical variables such
as tumour histological subtype. However, intratumoral
TILs did not. We have also shown that increased levels
of both intratumoral and stromal TILs are associated
with a better prognosis; however, this is only statistically
significant for intratumoral TILs.
These results add weight to the argument that the im-
mune system plays an important role in ovarian cancer.
They also support the idea that different subtypes of
ovarian cancer are variably immunogenic and that the
immune response can help define different subtypes.
The difference between stromal and intratumoral TIL
effects, despite their correlated levels in both primary
and secondary tumours, is interesting, and warrants
further investigation. The greater prognostic effect of
intratumoral TILs may explained by the biological ration-
ale that T-cell activation necessitates physical contact with
target cells in order to engage the T cell receptor [26]. In
contrast, the lesser prognostic effect of stromal TILs
might be explained in two ways; either they are in-transit
to tumour cells hence will eventually become intratumoral
TILs, or that they have been ‘excluded’ from the tumour
microenvironment by factors secreted by tumour cells
and/or other stromal cells, as a means of evading immune
attack [26]. Further work to elucidate the distinct roles of
intratumoral and stromal TILs is needed.
The results suggest that a clinically useful immune
prognostic indicator in epithelial ovarian cancer could
Table 3 Association between tumour infiltrating lymphocyte
levels in primary and secondary tumours for stromal and
intratumoral infiltrating lymphocytes
Primary tumour
infiltrating lymphocytes
Secondary tumour infiltrating lymphocytes
<5% 5–9% ≥10% Total
Stromal
< 5% 21 25 39 85
5–9% 7 17 39 63
≥10% 4 8 37 49
Total 32 50 115 197
Intra-tumoral
< 5% 96 55 19 170
5–9% 6 4 5 15
≥10% 3 5 3 11
Total 105 64 27 196
Table 4 Intra-tumoral and stromal tumour infiltrating lymphocyte
levels by histotype
Histotype Tumour infiltrating lymphocyte level Number (%)
<5% 5–9% ≥10% Total
Stromal
Low-grade serous 13 (57) 8 (35) 2 (9) 23
High-grade serous 122 (39) 85 (27) 107 (34) 314
Mucinous 28 (58) 12 (25) 8 (17) 48
Endometrioid 68 (50) 29 (22) 38 (28) 135
Clear cell 58 (71) 12 (15) 12 (14) 82
Other 33 (48) 18 (26) 18 (26) 69
Borderline 30 (83) 4 (11) 2 (6) 36
Total 352 (50) 168 (24) 187 (26) 707
Intra-tumoral
Low-grade serous 20 (87) 1 (4) 2 (9) 23
High-grade serous 240 (76) 47 (15) 27 (9) 314
Mucinous 43 (90) 3 (6) 2 (4) 48
Endometrioid 108 (80) 20 (15) 7 (5) 135
Clear cell 69 (84) 8 (10) 5 (6) 82
Other 58 (84) 8 (12) 3 (4) 69
Borderline 34 (94) 2 (6) 0 (0) 36
Total 572 (81) 89 (13) 46 (7) 707
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be developed using this technique, but larger scale
studies are needed to replicate these results. Thus, fur-
ther studies evaluating the potential of TILs as predic-
tors of treatment response are warranted.
Conclusion
This study is the largest collection of epithelial ovarian
tumour samples evaluated for TILs. We have shown that
stromal and intratumoral TIL levels are correlated and
that their levels correlate with clinical variables such as
tumour histological subtype. We have also shown that
increased levels of both intratumoral and stromal TILs
are associated with a better prognosis; however, this is
only statistically significant for intratumoral TILs. This
study suggests that a clinically useful immune prognostic
indicator in epithelial ovarian cancer could be developed
using this technique.
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